A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
Recruiting
This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
12/07/2023
Locations: Velocity Clinical Research - Gaffney - PPDS, Gaffney, South Carolina +1 locations
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
Recruiting
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) in stable doses throughout at least 3 months prior... Read More
Gender:
All
Ages:
Between 40 years and 130 years
Trial Updated:
12/04/2023
Locations: Research Site, Rock Hill, South Carolina
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
Recruiting
Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with symptomatic COPD.
Gender:
All
Ages:
Between 40 years and 130 years
Trial Updated:
11/22/2023
Locations: Research Site, Rock Hill, South Carolina
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.
Recruiting
This is a research study to evaluate the efficacy and safety of the investigational drug Mitiperstat (AZD4831) in adult patients with chronic obstructive pulmonary disease.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
11/17/2023
Locations: Research Site, Fort Mill, South Carolina
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Breathe Easier II: A Dyad-based Multiple Behavior Intervention
Recruiting
This pilot randomized control trial (RCT) will test a 12-week, multiple behavior intervention physical activity and stress management for survivors with early stage lung cancer (stages I-III) and their family members (1 survivor + 1 family member or friend = 1 dyad). The long-term goal of this research is to improve health outcomes for survivors of lung cancer and their family members. The goals of the intervention, Breathe Easier, are symptom reduction (less breathlessness, less fatigue, less... Read More
Gender:
All
Ages:
21 years and above
Trial Updated:
07/11/2023
Locations: University of South Carolina, Columbia, South Carolina
Conditions: Lung Cancer, Nonsmall Cell, COPD, Self-Management, Physical Inactivity, Stress, Quality of Life
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
Recruiting
The purpose of this study is to compare CHF 5993 with CHF 1535 in improving lung function, reducing moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes in the target subject population.
Gender:
All
Ages:
40 years and above
Trial Updated:
02/06/2023
Locations: Chiesi Clinical Trial Site 840222, Anderson, South Carolina +6 locations
Conditions: COPD, COPD Exacerbation